Skip to main content
SpringerLink
Log in

Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter"

  • Letter to the Editor
  • Published:
Drug Safety Aims and scope Submit manuscript

A Letter to the Editor to this article was published on 10 January 2017

The Original Article was published on 09 January 2016

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

References

  1. Sarker A, O’Connor K, Ginn R, Scotch M, Smith K, Malone D, et al. Social media mining for toxicovigilance: automatic monitoring of prescription medication abuse from Twitter. Drug Saf. 2016;39:231–40.

    Article  PubMed  PubMed Central  Google Scholar 

  2. Schwan S, Sundström A, Stjernberg E, Hallberg E, Hallberg P. A signal for an abuse liability for pregabalin: results from the Swedish spontaneous adverse drug reaction reporting system. Eur J Clin Pharmacol. 2010;66:947–53.

    Article  PubMed  Google Scholar 

  3. Spagnolo PA, Badiani A, Nencini P. Polydrug abuse by intravenous use of heroin and tropicamide-containing eyedrops. Clin Neuropharmacol. 2013;36:100–1.

    Article  PubMed  Google Scholar 

  4. Jouanjus E, Pourcel L, Saivin S, Molinier L, Lapeyre-Mestre M. Use of multiple sources and capture–recapture method to estimate the frequency of hospitalizations related to drug abuse. Pharmacoepidemiol Drug Saf. 2012;21:733–41.

    Article  PubMed  Google Scholar 

  5. Layton D, Osborne V, Al-Shukri M, Shakir SAW. Indicators of drug-seeking aberrant behaviours: the feasibility of use in observational post-marketing cohort studies for risk management. Drug Saf. 2014;37:639–50.

    Article  PubMed  PubMed Central  Google Scholar 

  6. Manasco AT, Griggs C, Leeds R, Langlois BK, Breaud AH, Mitchell PM, et al. Characteristics of state prescription drug monitoring programs: a state-by-state survey. Pharmacoepidemiol Drug Saf. 2016;25:847–51.

    Article  PubMed  Google Scholar 

  7. Cicero TJ, Dart RC, Inciardi JA, Woody GE, Schnoll S, Muñoz A. The development of a comprehensive risk-management program for prescription opioid analgesics: researched abuse, diversion and addiction-related surveillance (RADARS). Pain Med. 2007;8(2):157–70.

    Article  PubMed  Google Scholar 

  8. Jouanjus E, Gibaja V, Kahn J-P, Haramburu F, Daveluy A. Signal identification in addictovigilance: the functioning of the French system. Thérapie. 2015;70:113–31.

    Article  PubMed  Google Scholar 

  9. Schifano F, Papanti GD, Orsolini L, Corkery JM. The consequences of drug misuse on post-marketing surveillance. Expert Rev Clin Pharmacol. 2016;9:867–71.

    Article  CAS  PubMed  Google Scholar 

  10. Jouanjus E, Leymarie F, Tubery M, Lapeyre-Mestre M. Cannabis-related hospitalizations: unexpected serious events identified through hospital databases. Br J Clin Pharmacol. 2011;71:758–65.

    Article  PubMed  PubMed Central  Google Scholar 

  11. Palmaro A, Moulis G, Despas F, Dupouy J, Lapeyre-Mestre M. Overview of drug data within French health insurance databases and implications for pharmacoepidemiological studies. Fundam Clin Pharmacol. 2016;30(6):616–24.

    Article  CAS  PubMed  Google Scholar 

  12. Van Hout MC. An Internet study of user’s experiences of the synthetic cathinone 4-methylethcathinone (4-MEC). J Psychoactive Drugs. 2014;46:273–86.

    Article  PubMed  Google Scholar 

  13. Schifano F, D’Offizi S, Piccione M, Corazza O, Deluca P, Davey Z, et al. Is there a recreational misuse potential for pregabalin? Analysis of anecdotal online reports in comparison with related gabapentin and clonazepam data. Psychother Psychosom. 2011;80:118–22.

    Article  PubMed  Google Scholar 

  14. CSP. Article R.5132-112. 2012. Available at: https://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=LEGITEXT000006072665&idArticle=LEGIARTI000006915740&dateTexte=&categorieLien=cid. Accessed 03 Jan 2017.

  15. CSP. Article R.5132-113. 2012. Available at: https://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=LEGITEXT000006072665&idArticle=LEGIARTI000006915743. Accessed 03 Jan 2017.

  16. CSP. Article R1341-28. Available at: https://www.legifrance.gouv.fr/affichCodeArticle.do?cidTexte=LEGITEXT000006072665&idArticle=LEGIARTI000028603635&dateTexte=&categorieLien=cid. Accessed 03 Jan 2017.

  17. Butler SF, Budman SH, Licari A, Cassidy TA, Lioy K, Dickinson J, et al. National Addictions Vigilance Intervention and Prevention Program (NAVIPPRO): a real-time, product-specific, public health surveillance system for monitoring prescription drug abuse. Pharmacoepidemiol Drug Saf. 2008;17:1142–54.

    Article  PubMed  Google Scholar 

  18. Micallef J, Frauger E, Palmaro A, Boucherie Q, Lapeyre Mestre M. Example of an investigation of an «emergent» phenomenon in addiction vigilance: the case of methylphenidate. Therapie. 2015;70:191–202.

    Article  Google Scholar 

  19. Lapeyre-Mestre M, Dupui M. Drug abuse monitoring: which pharmacoepidemiological resources at the European level? Thérapie. 2015;70:147–65.

    Article  PubMed  Google Scholar 

  20. Roussin A, Doazan-d’Ouince O, Géniaux H, Halberer C, French Network of Centre for Evaluation and Information on Pharmacodependence (Addictovigilance Centres). Evaluation of abuse and dependence in addiction monitoring systems: tramadol as an example. Therapie. 2015;70:203–21.

    Article  Google Scholar 

  21. Pauly V, Pradel V, Pourcel L, Nordmann S, Frauger E, Lapeyre-Mestre M, et al. Estimated magnitude of diversion and abuse of opioids relative to benzodiazepines in France. Drug Alcohol Depend. 2012;126:13–20.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. CEIP-Addictovigilance, Service de Pharmacologie Médicale et Clinique, CHU Toulouse, Toulouse, France

    Emilie Jouanjus, Camille Ponté, Anne Roussin & Maryse Lapeyre-Mestre

  2. Equipe de Pharmacoépidémiologie, UMR1027-Université Paul Sabatier Toulouse III, Toulouse, France

    Emilie Jouanjus, Camille Ponté, Anne Roussin & Maryse Lapeyre-Mestre

  3. CEIP-Addictovigilance, Service de Pharmacologie, CHU Grenoble, Grenoble, France

    Michel Mallaret

  4. CEIP-Addictovigilance, Service de Pharmacologie Clinique, CHU Timone, Marseille, France

    Joëlle Micallef

  5. INT-CNRS/AMU Aix-Marseille, Institut de Neurosciences de la Timone, Marseille, France

    Joëlle Micallef

Authors
  1. Emilie Jouanjus
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Michel Mallaret
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Joëlle Micallef
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Camille Ponté
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Anne Roussin
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Maryse Lapeyre-Mestre
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Emilie Jouanjus.

Ethics declarations

Funding

No sources of funding were used in the preparation of this letter.

Conflict of interest

Emilie Jouanjus, Michel Mallaret, Joëlle Micallef, Camille Ponté, Anne Roussin, and Maryse Lapeyre-Mestre have no conflicts of interest that are directly relevant to the content of this letter.

Additional information

This letter refers to the article available at doi:10.1007/s40264-015-0379-4.

This letter refers to the reply article available at doi:10.1007/s40264-016-0498-6.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Jouanjus, E., Mallaret, M., Micallef, J. et al. Comment on: "Social Media Mining for Toxicovigilance: Automatic Monitoring of Prescription Medication Abuse from Twitter". Drug Saf 40, 183–185 (2017). https://doi.org/10.1007/s40264-016-0497-7

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s40264-016-0497-7

Keywords

Search

Navigation